CBIO
NASDAQ
US
Crescent Biopharma, Inc. - Common Stock
$19.40
▲ +$0.08
(+0.41%)
Vol 209K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$164.8M
ROE
-230.8%
Margin
-90786.4%
D/E
0.00
Beta
-5.10
52W
$10–$21
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
PROK
Prokidney Corp
$673.9M
TECX
Tectonic Therapeutic Inc
$390.4M
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
ZURA
Zura Bio Ltd
$340.7M
UPB
Upstream Bio Inc
$1.5B
RIGL
Rigel Pharmaceuticals Inc
P/E 6.9
$777.4M
LRMR
Larimar Therapeutics Inc
$326.1M
TRDA
Entrada Therapeutics Inc
$392.9M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-2.57 | $-0.54 | +$2.03 |
| Sep 2025 | $-2.02 | $-1.27 | +$0.75 |
| Jun 2025 | $-1.80 | $-4.93 | $-3.13 |
| Mar 2025 | $-5.10 | $-4.00 | +$1.10 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|
| Revenue | — | — | — | $10.8M |
| Net Income | -$17.9M | -$21.8M | -$24.6M | -$92.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -230.8% | -230.8% | -230.8% | -230.8% | -230.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -90786.4% | -90786.4% | -90786.4% | -90786.4% | -90786.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.21 | 2.29 | 2.29 | 9.21 | 6.63 | 6.63 |
Key Ratios
ROA (TTM)
-177.4%
P/S (TTM)
16476.52
P/B
0.4
EPS (TTM)
$-42.26
CF/Share
$-1.37
52W High
$21.40
52W Low
$9.81
$9.81
52-Week Range
$21.40
Financial Health
Free Cash Flow
-$98.9M
Net Debt
-$211.5M
Cash
$213.2M
Total Debt
$1.6M
As of Dec 31, 2025
How does CBIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CBIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16476.5
▲
128122%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0.4
▼
84%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CBIO profitability vs Biotechnology peers
ROE
-230.8%
▼
243%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-90786.4%
▼
31560%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-177.4%
▼
280%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CBIO financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.6
▲
49%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
-5.1
▼
626%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CBIO fundamentals radar
CBIO
Peer median
Industry
CBIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CBIO vs peers: key metrics
Top Holders
Top 5: 48.77%FMR, LLC
15.00%
$62.7M
BVF Inc.
9.97%
$41.7M
Fairmount Funds Management …
9.97%
$41.7M
VR Adviser, LLC
7.74%
$32.3M
FCPM III Services B.V.
6.09%
$25.4M
As of Dec 31, 2025
Dividends
$167.00
/ year
Jan 13, 2023
$24.0000
Sep 21, 2022
$143.0000
Latest News
No related news yet